trending Market Intelligence /marketintelligence/en/news-insights/trending/k4PZUfXS9MhFV0Q9VWkIQQ2 content esgSubNav
In This List

Japan's Hisamitsu seeks US FDA nod for schizophrenia therapy

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Japan's Hisamitsu seeks US FDA nod for schizophrenia therapy

Japan's Hisamitsu Pharmaceutical Co. Inc. and its U.S. unit Noven Pharmaceuticals Inc. submitted an application seeking U.S. Food and Drug Administration approval for schizophrenia treatment HP-3070.

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves.

HP-3070, or asenapine maleate, is a patch placed on the skin to deliver medication into the bloodstream. The transdermal therapy was previously shown to improve symptoms of the disorder in a late-stage study.